Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10368095 | 0.85 | MEN1 (0.33) | MEN1KMT2ALMNACA2 | |
| SCHEMBL1068424 | 0.81 | CA2 (0.35) | MEN1KMT2ACA2 | |
| SCHEMBL7144799 | 0.80 | CA2 (0.38) | MEN1KMT2ACA2 | |
| SCHEMBL13570177 | 0.77 | CA2 (0.30) | CA2 | |
| SCHEMBL31273984 | 0.75 | MEN1 (0.38) | ALDH1A1MEN1KMT2ALMNACA2 | |
| SCHEMBL1830869 | 0.75 | MEN1 (0.38) | ALDH1A1MEN1KMT2ALMNACA2 | |
| SCHEMBL3434112 | 0.75 | MEN1 (0.38) | ALDH1A1MEN1KMT2ALMNACA2 | |
| SCHEMBL10061724 | 0.75 | CYP1A2 (0.40) | CA2CYP2D6DPP4DPP8DPP9 | |
| SCHEMBL15946939 | 0.70 | CHRM2 (0.39) | ALDH1A1MEN1KMT2ALMNACA2 | |
| SCHEMBL10061723 | 0.69 | CXCR3 (0.36) | CYP2D6DPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569715-B2 | Compositions containing silanes | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2009-08-04 | — | — | US | disclosed |
| EP-2044012-A2 | COMPOSITIONS CONTAINING SILANES | 3M Innovative Properties Company (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008005851-A2 | COMPOSITIONS CONTAINING SILANES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20080008891-A1 | COMPOSITIONS CONTAINING SILANES | 3M INNOVATIVE PROPERTIES COMPANY | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080008891-A1 | COMPOSITIONS CONTAINING SILANES | PFAS, SGMS2, NAF1 | ALDH1A1 3883/4885MEN1 500/4885KMT2A 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.